IASO Bio's in vivo CAR-T grabs FDA and NMPA clearances at the same time

IASO208, a CD20-targeting in vivo CAR-T built on IASO Bio's InTelliCAR lentiviral vector platform, now carries active IND clearances in the United States and China simultaneously. The FDA cleared the IND implicitly in September 2026. China's NMPA followed this month through the country's 30-day expedited review pathway. With both jurisdictions live, IASO can build on its China investigator-initiated trial dataset to launch Phase Ib work in the US, with larger studies planned on both sides.

The supporting dataset is small. Eleven patients have been dosed in the ongoing China IIT, all without apheresis or lymphodepleting conditioning, each receiving a single intravenous infusion. Early results showed favorable tolerability and promising anti-tumor activity, enough to earn an oral presentation slot at the 2026 ASH Annual Meeting under Abstract #705.

Every CAR-T therapy approved so far is ex vivo — T cells are engineered outside the body and then reinfused. In vivo flips that: the vector does the reprogramming inside the patient, an approach that still carries substantial unknowns at scale. Eleven patients is enough to anchor a Phase Ib design and convince regulators that proceeding is reasonable, but it is not a signal.

The route IASO took carries its own weight. China's 30-day expedited IND track is a relatively recent mechanism aimed at innovative candidates with urgent development rationale, and clearing it suggests the NMPA treated the in vivo construct as scientifically credible rather than merely administratively complete. IASO already has standing with the agency: its ex vivo BCMA-targeting product equecabtagene autoleucel is approved in China for relapsed/refractory multiple myeloma, handing the company real CMC and regulatory infrastructure for IASO208.

The open question is whether the US Phase Ib can produce safety and efficacy data in B-NHL patients strong enough for the tougher FDA scrutiny a registrational filing would demand. The ASH oral presentation will be the first public look at whether the 11-patient China IIT dataset can carry the dual-jurisdiction path IASO has now unlocked.